MYC and plasma cell myeloma: By targeting different aspects of MM cell biology, many of which are ultimately controlled by MYC, the research community expects to achieve higher response rates, delay resistance appearance and resensitize patients who have exhausted all other alternatives, attempting to prolong survival and ultimately getting one step closer to rendering myeloma a curable disease.